Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2016

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2016
Published Jun 08, 2016
92 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2016, provides an overview of the Liver Failure (Hepatic Insufficiency) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency)
- The report reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Liver Failure (Hepatic Insufficiency) therapeutics and enlists all their major and minor projects
- The report assesses Liver Failure (Hepatic Insufficiency) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Liver Failure (Hepatic Insufficiency)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identi

  
Source:
Document ID
GMDHC8181IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Liver Failure (Hepatic Insufficiency) Overview91
Therapeutics Development102
  Pipeline Products for Liver Failure (Hepatic Insufficiency) Overview101
  Pipeline Products for Liver Failure (Hepatic Insufficiency) Comparative Analysis111
Liver Failure (Hepatic Insufficiency) Therapeutics under Development by Companies121
Liver Failure (Hepatic Insufficiency) Therapeutics under Investigation by Universities/Institutes131
Liver Failure (Hepatic Insufficiency) Pipeline Products Glance144
  Late Stage Products141
  Clinical Stage Products151
  Early Stage Products161
  Unknown Stage Products171
Liver Failure (Hepatic Insufficiency) Products under Development by Companies181
Liver Failure (Hepatic Insufficiency) Products under Investigation by Universities/Institutes191
Liver Failure (Hepatic Insufficiency) Companies Involved in Therapeutics Development2012
  Alfact Innovation201
  Cell2B S.A.211
  Conatus Pharmaceuticals Inc.221
  Digna Biotech, S.L.231
  Immune Pharmaceuticals Inc.241
  Meda AB251
  Ocera Therapeutics, Inc.261
  PledPharma AB271
  Promethera Biosciences S.A.281
  Silence Therapeutics Plc291
  TGV-Laboratories301
  Ventria Bioscience311
Liver Failure (Hepatic Insufficiency) Therapeutics Assessment329
  Assessment by Monotherapy Products321
  Assessment by Target332
  Assessment by Mechanism of Action352
  Assessment by Route of Administration372
  Assessment by Molecule Type392
Drug Profiles4127
  ALF-5755 - Drug Profile411
    Product Description411
    Mechanism of Action411
    R&D Progress412
  Antisense RNAi Oligonucleotide for Liver Diseases - Drug Profile431
    Product Description431
    Mechanism of Action431
    R&D Progress431
  Cardiotrophin-1 - Drug Profile441
    Product Description441
    Mechanism of Action441
    R&D Progress442
  Cell Therapy for Liver Failure - Drug Profile461
    Product Description461
    Mechanism of Action461
    R&D Progress461
  emricasan - Drug Profile471
    Product Description471
    Mechanism of Action471
    R&D Progress472
  F-573 - Drug Profile491
    Product Description491
    Mechanism of Action491
    R&D Progress491
  Hep-114 - Drug Profile501
    Product Description501
    Mechanism of Action501
    R&D Progress501
  HepaStem - Drug Profile511
    Product Description511
    Mechanism of Action511
    R&D Progress512
  ImmuneSafe - Drug Profile531
    Product Description531
    Mechanism of Action531
    R&D Progress532
  MTL-CEBPA - Drug Profile551
    Product Description551
    Mechanism of Action551
    R&D Progress551
  Oligonucleotide for Liver Failure - Drug Profile561
    Product Description561
    Mechanism of Action561
    R&D Progress561
  ornithine phenylacetate - Drug Profile571
    Product Description571
    Mechanism of Action571
    R&D Progress572
  PP-100 - Drug Profile591
    Product Description591
    Mechanism of Action591
    R&D Progress591
  Recombinant Protein to Inhibit JNK for Liver Failure - Drug Profile601
    Product Description601
    Mechanism of Action601
    R&D Progress601
  RNAi Oligonucleotides to Inhibit MAP Kinase 4 for Liver Failure - Drug Profile611
    Product Description611
    Mechanism of Action611
    R&D Progress611
  silibinin - Drug Profile621
    Product Description621
    Mechanism of Action621
    R&D Progress621
  Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure - Drug Profile631
    Product Description631
    Mechanism of Action631
    R&D Progress631
  Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure and Neurodegenerative Diseases - Drug Profile641
    Product Description641
    Mechanism of Action641
    R&D Progress642
  VEN-100 - Drug Profile661
    Product Description661
    Mechanism of Action661
    R&D Progress662
Liver Failure (Hepatic Insufficiency) Recent Pipeline Updates6812
Liver Failure (Hepatic Insufficiency) - Dormant Projects801
Liver Failure (Hepatic Insufficiency) Discontinued Products811
Liver Failure (Hepatic Insufficiency) Product Development Milestones829
  Featured News &Press Releases821
    Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases821
    Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting821
    Oct 05, 2015: Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases831
    Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan842
    Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan861
    Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting861
    Apr 11, 2013: Gene inhibition helps to improve liver regeneration871
    Apr 02, 2013: ALF-5755 phase II completion881
    Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury881
    Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure892
Appendix912
  Methodology911
  Coverage911
  Secondary Research911
  Primary Research911
  Expert Panel Validation911
  Contact Us911
  Disclaimer921

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Liver-Failure-Hepatic-Insufficiency-Pipeline-Review-H1-2016-2088-15913>
  
APA:
Global Markets Direct - Market Research. (2016). Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Liver-Failure-Hepatic-Insufficiency-Pipeline-Review-H1-2016-2088-15913>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.